Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton

References

• Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584–93
   PubMed Web of Science ®Google Scholar
• Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375–9
   PubMed Web of Science ®Google Scholar
• Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Clin Orthop Relat Res 2003; 415(Suppl): S138–47
   Google Scholar
• Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumours. J Natl Cancer Inst 2005; 97: 59–69
   PubMed Web of Science ®Google Scholar
• Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165–76
   PubMed Web of Science ®Google Scholar
• Koizumi M, Takahashi S, Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 2003; 23: 4095–9
   PubMed Web of Science ®Google Scholar
• Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 2002; 94: 2521–3
   PubMed Web of Science ®Google Scholar
• Fohr B, Dunstan C, Seibel M. Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003; 88: 5059–75
   PubMed Web of Science ®Google Scholar
• O’ Regan A. The role of osteopontin in lung disease. Cytokine Growth Factor Rev 2003; 14: 479–88
   PubMed Web of Science ®Google Scholar
• Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96: 3540–5
   PubMed Web of Science ®Google Scholar
• Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffau M, Layton M, et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL),osteprotegerin and macrophage protein 1-alpha (MIP-1α) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004; 126: 686–9
   PubMed Web of Science ®Google Scholar
• Nagai M, Kyakumoto S, Sato N. Cancer cells responsible for humoral hypercalcaemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun 2000; 269: 532–6
   PubMed Web of Science ®Google Scholar
• Huang L, Cheng YY, Chow LT, Lee KM, Zheng MH. Tumor cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases. J Clin Pathol 2002; 55: 877–8
   PubMed Web of Science ®Google Scholar
• Milligan SA, Nopajaroonsri C. Inhibition of NF-(B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro. Anticancer Res. 2001; 21: 39–44
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor kappa B ligand and osteprotegerin: Potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001; 92: 460–70
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309–19
   PubMed Web of Science ®Google Scholar
• Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPG is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315–23
   PubMed Web of Science ®Google Scholar
• Bucay N, Sarosi I, Dunstan CR, Morony S, Zarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260–8
   PubMed Web of Science ®Google Scholar
• Jung K, Lein M, von Hosslin K, Brux B, Schnorr D, Loening SA, et al. Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin Chem 2001; 47: 2061–3
   PubMed Web of Science ®Google Scholar
• Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index. Blood 2003; 102: 1064–9
   PubMed Web of Science ®Google Scholar
• Goltzman D, Karaplis AC, Kremer R, Rabbani SA. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 2000; 88: 2903–8
   PubMedGoogle Scholar
• Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodelling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19: 1969–76
   PubMed Web of Science ®Google Scholar
• Terpos E, Dimopoulos MA. Myeloma bone disease: Pathophysiology and management. Ann Oncol 2005; 16: 1223–31
   PubMed Web of Science ®Google Scholar
• Fedarko NS, Jain A, Karadag A, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate and lung cancer. Clin Cancer Res 2001; 7: 4060–6
   PubMed Web of Science ®Google Scholar
• Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, et al. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 2004; 10: 1588–96
   PubMed Web of Science ®Google Scholar
• Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct in patients with multiple myeloma or breast-cancer related bone metastases. Cancer 2003; 97: 887–92
   PubMed Web of Science ®Google Scholar
• Generali DG, Tedoldi S, Tampellini M. Circadian rhythm of bone turnover markers in breast cancer patients with bone metastases and in control subjects. ASCO annual meeting 2005; 737(Suppl): 116–7
   Google Scholar
• Lonning P, Geisler J, Krag LE, Erikstein B, Bremmes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23: 5126–37
   PubMed Web of Science ®Google Scholar
• Piovesan A, Berruti A, Torta M, Connone R, Sperone P, Panero A, et al. Comparison of assay of total and bone-specific alkaline phosphatase in the assessment of osteoblast activity in patients with metastatic bone disease. Calcif Tissue Int 1997; 61: 362–9
   PubMed Web of Science ®Google Scholar
• Lara PN, Longmate J, Stadler W. Markers of bone metabolism predict survival in hormone refractory prostate cancer (HRPC): Results from a randomized California Cancer Consortium & Univ. of Chicago trial. ASCO annual meeting ;(Suppl) 2005; 4569: 423–4
   Google Scholar
• Coleman R, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the biphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925–35
   PubMed Web of Science ®Google Scholar